Histotripsy and the IDEAL Framework: A Clarion Call for the Responsible and Evidence-Based Application of New Technology

Abstract

The evaluation of novel health technologies is increasingly complicated by a landscape of pervasive social media influence and intense product marketing, factors that may distort evidence appraisal and contribute to suboptimal medical decision-making and patient outcomes. Within this context, interest in histotripsy, a novel technology approved for the treatment of liver tumors, has expanded rapidly. This accelerated adoption has outpaced the available evidence, challenging established principles of safety, efficacy, and appropriate patient selection and has generated substantial debate within the oncologic community. In this editorial, we provide an overview of the technology and available data, examine the external forces contributing to its accelerated application, and propose a well established, structured, evidence-based framework to guide its rigorous evaluation, responsible adoption, and optimal clinical implementation.